8-K: Compass Therapeutics' Tovecimig Achieves Primary Endpoint in Phase 2/3 Biliary Tract Cancer Study

Compass Therapeutics announces that tovecimig, in combination with paclitaxel, met its primary endpoint in a Phase 2/3 study for patients with biliary tract cancer (BTC), demonstrating a statistically significant improvement in overall response rate (ORR) compared to paclitaxel alone.

Summary

• Compass Therapeutics announced positive top-line data from its Phase 2/3 COMPANION-002 trial of tovecimig in combination with paclitaxel for patients with advanced biliary tract cancer (BTC).
• The study enrolled 168 adult patients, randomized 2:1 to receive either tovecimig plus paclitaxel (n=111) or paclitaxel alone (n=57).
• The primary endpoint, overall response rate (ORR), was 17.1% for the tovecimig combination arm compared to 5.3% for the paclitaxel alone arm, a statistically significant improvement (p=0.031).
• The study is ongoing to assess secondary endpoints, including progression-free survival (PFS), overall survival (OS), and duration of response (DoR), with data expected in Q4 2025.
• The safety profile of tovecimig was consistent with prior studies, and an independent Data Monitoring Committee (DMC) recommended continuation of the study without modification after reviewing safety data.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results, indicating a potential new treatment option for a difficult-to-treat cancer. The statistically significant improvement in ORR and the consistent safety profile contribute to a positive outlook.

Positives

• Statistically significant improvement in ORR with tovecimig plus paclitaxel compared to paclitaxel alone (17.1% vs. 5.3%, p=0.031).
• Lower progressive disease rates in the tovecimig arm (16.2%) compared to the paclitaxel arm (42.1%).
• Safety profile of tovecimig consistent with prior studies.
• Independent DMC recommended continuation of the study without modification after reviewing safety data.

Negatives

• Secondary endpoint data (PFS, OS, DoR) are not yet mature and will be reported in Q4 2025.
• 14.4% of patients in the tovecimig arm and 15.8% of patients in the paclitaxel arm were not evaluable.

Risks

• The secondary endpoint data are not yet mature, and the trial requires a threshold of events in 80% of patients to trigger the secondary endpoint analyses.
• The company's ability to develop, complete clinical trials for, obtain approvals for and commercialize any of its product candidates is subject to competition in the industry and market conditions.
• The company's ability to raise the additional funding it will need to continue to pursue its business and product development plans is uncertain.

Future Outlook

The company anticipates reporting data from the secondary endpoints (PFS, OS, and DoR) in Q4 2025 and looks forward to discussing the data with regulatory authorities.

Management Comments

• Thomas Schuetz, MD, PhD, CEO of Compass, stated that the positive primary endpoint data highlights the potential of tovecimig to provide a much-needed treatment option for patients with BTC.
• Juan Valle, MD, Chief Medical Officer of the Cholangiocarcinoma Foundation, expressed optimism about tovecimig's continued progress in advancing new treatment options for BTC.

Industry Context

Biliary tract cancer has limited treatment options, particularly in the second-line setting, where approximately 85% of patients lack an FDA-approved treatment if their tumors do not harbor an actionable mutation. Current combinations of therapeutics used off-label in this setting generally have an ORR of ~5% or less and patients face a median overall survival of approximately six months.

Comparison to Industry Standards

• The 17.1% ORR achieved by tovecimig in combination with paclitaxel compares favorably to the ~5% ORR typically seen with off-label chemotherapy combinations used in the second-line setting for BTC.
• Historical data shows that FOLFOX chemotherapy in the second line setting has an ORR of 5%.

Stakeholder Impact

• Positive impact on patients with biliary tract cancer due to the potential for a new treatment option.
• Potential positive impact on shareholders due to the positive clinical trial results.
• Potential positive impact on the company's reputation and market position.

Next Steps

• The company will continue the COMPANION-002 study to assess secondary endpoints.
• The company expects to report data from the secondary endpoints (PFS, OS, and DoR) in Q4 2025.
• The company plans to discuss the data with regulatory authorities.

Key Dates

Keywords

tovecimig, biliary tract cancer, COMPANION-002, paclitaxel, overall response rate, clinical trial, oncology, Compass Therapeutics